(29 days)
Not Found
No
The document describes a quality control serum for laboratory testing and does not mention any AI or ML components.
No
Explanation: This device is a quality control material used to monitor the precision of laboratory testing procedures, not to treat or diagnose a medical condition in a patient.
No
This device is a quality control serum used to monitor the precision of laboratory testing procedures, not to diagnose a patient's medical condition. It ensures the accuracy of other diagnostic tests.
No
The device is a quality control serum, which is a physical substance used in laboratory testing, not a software program.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states it's for "monitoring the precision of laboratory testing procedures for the analytes listed in this package insert." This is a classic function of a quality control material used in laboratory testing.
- Device Description: It's a "quality control serum" prepared from biological materials (human serum) with added constituents. This type of material is used in vitro (outside the body) to assess the performance of diagnostic tests.
- Intended User / Care Setting: The intended user is involved in "laboratory testing procedures," which is where IVDs are used.
The fact that it's a quality control material for laboratory tests directly aligns with the definition of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
Liquichek Cardiac Markers Plus Control LT is intended for use as a quality control serum to monitor the precision of laboratory testing procedures for the analytes listed in this package insert.
Product codes (comma separated list FDA assigned to the subject device)
JJY
Device Description
Liquichek Cardiac Markers Plus Control LT is prepared from human serum with added constituents of human and animal origin, chemicals, preservatives and stabilizers. The control is provided in liquid form for convenience.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
laboratory testing procedures
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Real-time stablity studies were conducted to establish the thawed stablity claims (openvial and unopened). Accelerated stability studies were conducted to establish the shelflife claims at -20 to -50 °C. Based on the available data, product claims are as follows:
Thawed and Opened: 10 days at 2 to 8°C
Thawed and Unopened: 10 days at 2 to 8°C
Shelf Life Stability: 32.5 months at -20 to -50°C
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 862.1660 Quality control material (assayed and unassayed).
(a)
Identification. A quality control material (assayed and unassayed) for clinical chemistry is a device intended for medical purposes for use in a test system to estimate test precision and to detect systematic analytical deviations that may arise from reagent or analytical instrument variation. A quality control material (assayed and unassayed) may be used for proficiency testing in interlaboratory surveys. This generic type of device includes controls (assayed and unassayed) for blood gases, electrolytes, enzymes, multianalytes (all kinds), single (specified) analytes, or urinalysis controls.(b)
Classification. Class I (general controls). Except when intended for use in donor screening tests, quality control materials (assayed and unassayed) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.
0
Blo-Rad Laboratories Premarket Notification Section 510 (k) Liquichek Cardiac Markers Plus Control LT
Page 1 of 3
DEC 2 7 2012
510(k) Summary Liquichek Cardiac Markers Plus Control LT
1.0 Submitter
Bio-Rad Laboratories 9500 Jeronimo Road. Irvine, California 92618-2017 (949) 598-1200 Telephone: Fax: (949) 598-1557
Contact Person
Suzanne Parsons Regulatory Affairs Manager Telephone: (949) 598-1467
Date of Summary Preparation
December 20, 2012
2.0 Device Identification .
| Product Trade Name: | Liquichek Cardiac Markers Plus Control LT |
|---|---|
| Common Name: | Multi-Analyte Controls, All Kinds (Assayed) |
| Classifications: | Class I, Reserved |
| Product Code: | JJY |
| Regulation Number: | 21 CFR 862.1660 |
3.0 Device to Which Substantlal Equivalence is Claimed
Liquichek Cardiac Markers Plus Control LT Bio-Rad Laboratories Irvine, California
510 (k) Number: K050537
4.0 Description of Device
Liquichek Cardiac Markers Plus Control LT is prepared from human serum with added constituents of human and animal origin, chemicals, preservatives and stabilizers. The control is provided in liquid form for convenience.
5.0 Value Assignment
The mean values and the corresponding ±3SD ranges printed in this insert were derived from replicate analyses and are specific for this lot of product. The tests listed were performed by the manufacturer and/or independent laboratories using manufacturer supported reagents and a representative sampling of this lot of product. It is recommended that each laboratory establish its own acceptable ranges and use those provided only as guides. Laboratory established ranges may vary from those listed during the life of this control. Variations over time and between laboratories may be caused by differences in laboratory technique, instrumentation and reagents, or by manufacturer test method modifications.
1
6.0 Intended Use
Liquichek Cardiac Markers Plus Control LT is intended for use as a quality control serum to monitor the precision of laboratory testing procedures for the analytes listed in this package insert.
7.0 Comparison of the new device with the Predicate Device
Liquichek Cardiac Markers Plus Control LT claims substantial equivalence to the Liquichek Cardiac Markers Plus Control LT currently in commercial distribution (K050537). Table 1 (below) contains comparison of similarities and differences between the new and predicate device to which substantial equivalence is claimed.
Table 1: Simllarties and Differences between the new and predicate device
| Characteristics | Liquichek Cardiac Markers Plus Control LT
(New Device) | Liquichek Cardiac Markers Plus Control LT
(Predicate Device, K050537) |
|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | | |
| | Similarities | |
| Intended Use | This product is intended for use as a quality
control serum to monitor the precision of
laboratory testing procedures for the analytes
listed in the package insert. | This product is intended for use as a quality
control serum to monitor the precision of
laboratory testing procedures listed in the
package insert. |
| Form | Liquid | Liquid |
| Matrix | Human serum | Human serum |
| | Differences | |
| Fill Volume | 2.5 mL | 3 mL |
| Thawed and Unopened | 10 days at 2 - 8 °C | None |
| Thawed & Opened | 10 days at 2 - 8 °C | 20 days at 2 - 8 °C except for:
NT-proBNP: 15 days
TnI : 10 days
TnT: 4 days |
| Storage Unopened
(Shelf life) | At -20 to -50 °C until the expiration date | At -20 to -70 °C until the expiration date |
| Frozen allquot | None | 30 days at -20 to -70 °C |
| Analytes | Contains:
Troponin I
Creatine Kinase, Total (CK Total)
CK-MB Isoenzyme
Digitoxin
C-Reactive Protein(CRP)
Myoglobin
N-terminal pro-Brain Natriuretic Peptide (NT-proBNP)
Does not contain:
Troponin T
Homocysteine
BNP | Contains:
Troponin I
Creatine Kinase, Total (CK Total)
CK-MB Isoenzyme
Digitoxin
C-Reactive Protein(CRP)
Myoglobin
N-terminal pro-Brain Natriuretic Peptide (NT-proBNP)
Troponin T
Homocysteine
BNP (Not listed in the insert) |
2
8.0 Statement of Supporting Data
Real-time stablity studies were conducted to establish the thawed stablity claims (openvial and unopened). Accelerated stability studies were conducted to establish the shelflife claims at -20 to -50 °C. Based on the available data, product claims are as follows:
| Thawed and Opened: | 10 days at 2 to 8°C |
|---|---|
| Thawed and Unopened: | 10 days at 2 to 8°C |
| Shelf Life Stability: | 32.5 months at -20 to -50°C |
9.0 Conclusion
Based on the performance characteristics indicated above, the Bio-Rad Liquichek Cardiac Markers Plus Control LT is substantially equivalent to the predicate device, K050537.
All supporting data is retained on file at Bio-Rad Laboratories.
3
Image /page/3/Picture/0 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized symbol that resembles three overlapping human figures or abstract shapes, creating a sense of unity and connection.
DEPARTMENT OF HEALTH & HUMAN SERVICES
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-002
December 27, 2012
Bio-Rad Laboratories c/o Suzanne Parsons 9500 Jeronimo Road Irvine, CA 92618-2017
Re: K123663
Trade/Device Name: Liquichek Cardiac Markers Plus Control LT Regulation Number: 21 CFR 862.1660 Regulation Name: Quality control material Regulatory Class: Class I, reserved Product Code: JJY Dated: November 26, 2012 Received: November 28, 2012
Dear Ms. Suzanne Parsons:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
4
If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostics and Radiological Health at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
for Denise Johnson-lyles -S
Courtney H. Lias, Ph.D. Director Division of Chemistry and Toxicology Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health
Enclosure
5
Indications for Use
510(k) Number (if known): K123663
Device Name: Liquichek Cardiac Markers Plus Control LT
Indications for Use:
Liquichek Cardiac Markers Plus Control LT is intended for use as a quality control serum to monitor the precision of laboratory testing procedures for the analytes listed in this package insert.
Prescription Use X (21 CFR Part 801 Subpart D) And/Or
Over the Counter Use (21 CFR Part 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE; CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of In Vitro Diagnostics and Radiological Health (OIR)
Ruta Chander
Division Sign-Off Office of In Vitro Diagnostics and Radiological Health
123663 510(k)